Ratings Bionomics Australian S.E.

Equities

BNO

AU000000BNO5

Delayed Australian S.E. Other stock markets 11:40:06 24/08/2023 am IST			5-day change	1st Jan Change
0.01 ^AUD	-.--%		-.--%	-.--%

31/05	Bionomics Limited announced that it expects to receive $70 million in funding	CI
21/03	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	CI

Summary

The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIONOMICS	-.--%	7.66M	C-
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B	B+
REGENERON PHARMACEUTICALS, INC.	+21.73%	116B	B+
ARGENX SE	+22.18%	27.03B	B
BIONTECH SE	-21.81%	20.36B	B+
GENMAB A/S	-16.89%	16.43B	A-
BEIGENE, LTD.	-18.81%	15.91B	B
WUXI APPTEC CO., LTD.	-44.74%	15.6B	A-
SAREPTA THERAPEUTICS, INC.	+62.72%	14.94B	C+
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.59B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes